Esperion Therapeutics, Inc. (ESPR) Company Overview

What does Esperion Therapeutics do, and what is its status now?

Esperion Therapeutics, Inc. built a focused cardiometabolic pharmaceutical business around bempedoic acid, an oral, once-daily, non-statin medicine for lowering LDL cholesterol and reducing cardiovascular risk. Its two core U.S. products are NEXLETOL, which contains bempedoic acid, and NEXLIZET, a fixed-dose combination of bempedoic acid and ezetimibe. The company also acquired ENBUMYST, a bumetanide nasal spray for edema, in April 2026. The operating model combined direct U.S. commercialization with licensing, supply, milestone and royalty economics outside the United States.

ESPR is no longer publicly traded. On July 13, 2026, an ARCHIMED affiliate completed its acquisition of Esperion, making it a wholly owned subsidiary of Essence Parent Inc. Former Nasdaq shares converted into $3.16 in cash plus one non-transferable contingent value right per share; the CVRs can participate in up to $100 million of aggregate milestone payments. This article therefore reviews Esperion’s last public-company financial profile and the logic of its take-private transaction. The July 2026 merger-completion Form 8-K is the controlling source for that status change.

How did Esperion make money?

Which revenue streams mattered most?

Esperion reported one operating segment, but its revenue came through two distinct channels. First, it sold NEXLETOL and NEXLIZET to U.S. wholesalers and specialty distribution customers, recording product sales net of rebates, chargebacks, discounts, returns and other gross-to-net adjustments. Second, it monetized bempedoic acid internationally through collaboration agreements. Partners handled local development, regulatory work and commercialization, while Esperion received combinations of upfront payments, regulatory and sales milestones, royalties and revenue from supplying tablets.

The Q1 2026 mix was balanced: direct product sales represented 54.2% of revenue and collaboration revenue 45.8%. Collaboration diversified geography but remained less predictable because milestone timing could distort period-to-period comparisons. FY2025 collaboration revenue was $243.6 million, versus $159.6 million of U.S. product sales.

How did international partnerships create leverage?

Otsuka held Japanese rights and funded local development. The FY2025 Form 10-K disclosed a $60 million upfront payment, up to $450 million of additional milestones and royalties of 12% to 33% of Japanese net sales. Esperion received a $90 million payment in Q4 2025 tied to approval, pricing and cardiovascular-risk milestones. Daiichi Sankyo Europe commercialized NILEMDO and NUSTENDI, while other partners covered Canada, Australia, New Zealand and Israel. This model monetized global rights without a full Esperion sales organization in every market.

The FY2025 Form 10-K provides the clearest description of these contracts, while the company’s official products page identifies the commercial portfolio.

What did Esperion’s latest reported quarter show?

The quarter ended March 31, 2026 was Esperion’s last full public-company reporting period before the ARCHIMED transaction closed. Revenue grew, operating losses narrowed sharply and product demand improved year over year, yet the company still consumed cash and carried a heavy financing burden. The latest quarter therefore showed both the operating progress of the franchise and the balance-sheet constraints that made a strategic transaction consequential.

Why did operating performance improve?

Product sales increased by $8.5 million and collaboration revenue by $6.6 million. At the same time, R&D expense declined to $9.0 million in Q1 2026 from $12.6 million in Q1 2025 because of clinical and preclinical study timing. SG&A was essentially flat at $43.1 million, despite legal costs related to abbreviated new drug application litigation and higher media spending. Cost of goods sold increased to $34.6 million, partly because of inventory reserves. The result was a much smaller operating loss, although not yet a durable net profit.

What did cash flow reveal?

Esperion used $27.7 million of cash in operating activities during Q1 2026, compared with $22.6 million in Q1 2025. Financing activities provided $16.2 million, leaving cash down by $11.7 million during the quarter to $156.2 million at March 31, 2026. This is the key distinction between accounting improvement and financial self-sufficiency: the company’s income statement was moving toward operating break-even, but commercialization, inventory, litigation and financing obligations still absorbed cash. The Q1 2026 Form 10-Q contains the full unaudited statements and management discussion.

Which products, evidence and markets defined Esperion’s strategic position?

Why was the CLEAR Outcomes study the central asset?

NEXLETOL’s differentiation came from mechanism and evidence. Bempedoic acid inhibits ATP citrate lyase and is activated primarily in the liver. Phase 3 LDL-lowering studies included more than 3,000 patients, over 2,000 treated with NEXLETOL, and showed about 18% placebo-corrected LDL-C lowering when added to moderate- or high-intensity statins.

CLEAR Outcomes changed the proposition from cholesterol lowering alone to cardiovascular-risk reduction. The expanded labels covered adults unable to take recommended statin therapy with established cardiovascular disease or high event risk, widening the addressable population and strengthening differentiation from injectable alternatives. The official FDA prescribing information for NEXLETOL describes the approved indications and safety profile.

How did ENBUMYST change the portfolio?

Esperion completed the Corstasis acquisition on April 2, 2026 for $75 million upfront, with former Corstasis holders eligible for up to $180 million of regulatory or commercial milestones plus royalty- and licensing-derived payments. ENBUMYST had received FDA approval in September 2025. Strategically, the deal attempted to use Esperion’s U.S. commercial infrastructure for a second cardiovascular product and reduce dependence on one molecule. Financially, however, it added integration risk, contingent liabilities and another commercialization program only months before Esperion itself was acquired.

What turning points shaped Esperion’s business model?

Esperion’s history was a sequence of scientific validation, commercialization, partnership monetization and financing decisions, each changing its risk profile.

1. 2008
   The current company was formed around lipid-management assets and intellectual property transferred from Pfizer, establishing the bempedoic-acid platform.
2. 2013
   Esperion completed its initial public offering, giving the clinical-stage company access to public equity for late-stage development.
3. 2016–2019
   CLEAR Outcomes began and enrolled more than 14,000 patients, creating the evidence program that later differentiated the franchise.
4. 2020
   NEXLETOL and NEXLIZET launched in the United States, shifting Esperion from development-stage biotech to a commercial pharmaceutical company.
5. 2023–2024
   CLEAR Outcomes results were presented, followed by expanded FDA and European labels for cardiovascular-risk reduction; the evidence broadened the commercial narrative.
6. 2025
   U.S. product sales reached $159.6M and collaboration revenue reached $243.6M, while Japan milestones demonstrated the value of the partner model.
7. April 2026
   Esperion acquired Corstasis and ENBUMYST for $75.0M upfront, expanding beyond lipid management into edema treatment.
8. July 2026
   ARCHIMED completed the approximately $1.1B cash acquisition, and ESPR ceased trading on Nasdaq.

The timeline explains Esperion’s strategic value despite accumulated losses: a validated global franchise, direct U.S. commercial infrastructure and a second approved product. That path also required equity issuance, royalty monetization and debt, shifting future execution and financing risk to a healthcare-focused private owner. Esperion’s FY2025 earnings release captures the final full-year operating context before those 2026 transactions.

What gave Esperion a competitive advantage, and where was it vulnerable?

What was defensible?

The strongest asset combined a first-in-class oral mechanism, a large outcomes trial and expanded cardiovascular labeling. Partner leverage added local regulatory and commercial capabilities while preserving milestones, royalties and supply economics. Esperion’s specialized U.S. field organization could also carry products such as ENBUMYST.

Who competed with Esperion?

Competition came from multiple treatment classes rather than one direct rival. Generic statins and ezetimibe offered low-cost oral therapy. PCSK9 inhibitors and inclisiran delivered substantial LDL-C reduction through injections. Other branded cardiovascular therapies competed for physician attention, payer budgets and placement in treatment guidelines. This gave buyers and payers meaningful negotiating power. Esperion’s oral format and outcomes evidence reduced substitution risk for some statin-intolerant patients, but pricing, reimbursement and prescribing inertia remained important barriers.

Esperion disclosed a worldwide patent estate of approximately 12 issued U.S. patents, 12 pending U.S. applications, more than 40 issued foreign patents and more than 80 pending foreign applications at December 31, 2025. The original bempedoic-acid composition patent was scheduled to expire in December 2030, while newer high-purity manufacturing, composition and formulation patents were scheduled to run to June 2040. That layered estate was economically important, but enforceability and litigation outcomes were not guaranteed.

How financially strong was Esperion before the acquisition?

FY2025 results showed positive operating income, helped by collaboration revenue, but not net profitability. Revenue was $403.1 million, up from $332.3 million in FY2024. Operating income reached $60.3 million, while $84.6 million of interest expense contributed to a $22.7 million net loss. Financing arrangements captured a substantial portion of franchise economics.

What did the balance sheet imply?

Was the business approaching profitability?

At the operating line, yes: FY2025 operating margin was about 15.0%, calculated as $60.3 million of operating income divided by $403.1 million of revenue. But the quality of that margin mattered because collaboration revenue included one-time or milestone-related items. Q1 2026 operating margin fell back to about -8.2%, and net margin was approximately -31.5%. The company therefore needed continued product growth, recurring royalties, expense discipline and lower financing leakage to become sustainably profitable on a standalone basis.

Who owned Esperion, and how did governance affect the outcome?

Before the transaction, Esperion had one common share class with one vote per share and dispersed institutional ownership. The 2026 proxy used 257.4 million shares outstanding at March 31, 2026. BlackRock held 14.3 million shares, or 5.5%; Vanguard held 13.0 million, or 5.1%; directors and officers as a group held 4.4 million, or 1.6%.

What changed after the merger?

The board unanimously approved the May 1, 2026 merger agreement. At closing, public shareholders received cash and CVRs, former equity awards were cashed out or converted under the merger terms, and Esperion became wholly owned by Essence Parent. The former public directors ceased serving, and Justin Bateman and Ankit Pareek became the company’s directors. Public-market governance, quarterly voting and institutional influence were replaced by sponsor ownership and private-company oversight.

The 2026 proxy statement is the primary source for pre-merger ownership and compensation, while the May 1, 2026 merger Form 8-K describes the original transaction terms.

What risks and opportunities could change Esperion’s private-company value?

Where could value still compound?

Which risks were most material?

Distribution concentration was also important: three customers accounted for approximately 98% of FY2025 gross NEXLETOL and NEXLIZET sales. The structure is common in U.S. pharmaceuticals but heightens inventory, credit and contract-continuity risk. Reported collaboration revenue also did not equal cash retained because parts of future royalties had been monetized.

Which KPIs mattered most for valuation?

A public-company DCF needed to separate recurring U.S. product revenue from milestone-heavy collaboration revenue, estimate gross-to-net deductions, model royalties by territory, reflect royalty liabilities and debt, and probability-weight patent, regulatory and launch outcomes. After July 2026, those drivers determine private value and possible CVR payments rather than a listed share price.

Former shareholders also had a transaction-specific valuation variable: the CVR. The per-share cash consideration was fixed at $3.16, but additional value depends on defined milestones and is not guaranteed. The completion filing and CVR agreement therefore replaced a normal public-equity terminal-value debate with contractual milestone analysis.

What is the key takeaway from Esperion Therapeutics analysis?

Esperion converted a differentiated oral LDL-lowering mechanism into a clinically validated, globally partnered cardiovascular franchise. NEXLETOL and NEXLIZET produced growing U.S. sales, CLEAR Outcomes supported cardiovascular-risk indications, international partners generated royalties and milestones, and ENBUMYST broadened the portfolio.

The weakness was financial architecture. FY2025 revenue reached $403.1 million and operating income $60.3 million, but $84.6 million of interest expense contributed to a $22.7 million net loss. Q1 2026 revenue grew 23.2%, yet operations used $27.7 million of cash. Patent, payer, concentration and integration risks made the standalone path difficult even as a strategic buyer saw value.